These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10868556)

  • 21. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 22. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
    Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1199-202. PubMed ID: 12452546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
    Ciudad A; Montes JM; Olivares JM; Gómez JC;
    Eur Psychiatry; 2004 Sep; 19(6):358-65. PubMed ID: 15363475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global index of safety (GIS): a new instrument to assess drug safety.
    Sacristán JA; Gómez JC; Badía X; Kind P
    J Clin Epidemiol; 2001 Nov; 54(11):1120-5. PubMed ID: 11675163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
    Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.
    Montes JM; Ciudad A; Gascón J; Gómez JC;
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):667-74. PubMed ID: 12787855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
    Robinson KA
    Clin Ther; 2000 Nov; 22(11):1375-6. PubMed ID: 11117662
    [No Abstract]   [Full Text] [Related]  

  • 34. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
    Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
    Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
    Inada T; Beasley CM; Tanaka Y; Walker DJ
    Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
    Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
    Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.